Tag archive for ‘cancer vaccines for glioblastoma’
Agenus: Encouraging Data on Prophage, But What is the Path Forward (AGEN, Buy, $3.28)
Introduction On July 1, Agenus announced results from a non-randomized, phase 2 study of its therapeutic cancer vaccine Prophage in newly diagnosed glioblastoma multiforme patients. This was a 46 patient trial conducted at eight centers. All patients received Prophage plus standard of care (SOC) which is gross total resection to surgically remove as much of […]